Czech National Bank Buys 1,784 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Czech National Bank boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 66,902 shares of the pharmaceutical company’s stock after buying an additional 1,784 shares during the quarter. Czech National Bank’s holdings in Vertex Pharmaceuticals were worth $30,331,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Chesapeake Asset Management LLC grew its stake in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 33 shares in the last quarter. Colonial Trust Co SC lifted its position in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares in the last quarter. Total Investment Management Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter worth about $33,000. Financial Network Wealth Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 50.9% during the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 29 shares during the last quarter. Finally, Y.D. More Investments Ltd grew its position in Vertex Pharmaceuticals by 345.0% in the 3rd quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 69 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on VRTX. Evercore increased their price objective on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. HC Wainwright upped their target price on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $590.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Jefferies Financial Group started coverage on Vertex Pharmaceuticals in a report on Tuesday, March 10th. They set a “buy” rating and a $580.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on Vertex Pharmaceuticals from $570.00 to $596.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $554.30.

Vertex Pharmaceuticals Stock Up 1.4%

Vertex Pharmaceuticals stock opened at $454.97 on Thursday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $510.77. The firm has a 50 day moving average price of $468.97 and a 200-day moving average price of $441.56. The company has a market capitalization of $115.58 billion, a P/E ratio of 29.68, a P/E/G ratio of 1.92 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. During the same period last year, the firm posted $3.98 EPS. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Truist raised its price target on Vertex to $525 (from $490) and kept a Buy rating after encouraging Week‑36 interim results from Vertex’s Phase 3 RAINIER study — a clear positive catalyst supporting higher upside expectations. Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results
• Positive Sentiment: Multiple bullish writeups and retail/investor attention argue VRTX remains a buy—analysts and commentators point to durable CFTR franchise cash flows, pipeline upside and the recent dip as a potential buying opportunity. Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?
• Neutral Sentiment: Zacks and market headlines note VRTX outperformed the broader market in the latest session and is drawing elevated attention from Zacks users — this likely amplified buying interest but is descriptive rather than a fresh fundamental shift. Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Reports of large short‑interest changes are inconsistent/placeholder in recent feeds (reported zeros/NaN), so there’s no clear short‑squeeze signal — effectively neutral on near‑term price pressure.
• Negative Sentiment: Competition risk: Maze Therapeutics reported positive Phase II data for an APOL1‑mediated kidney disease drug that targets the same pathway Vertex is pursuing — the news highlights competitive risk to Vertex’s AMKD franchise, which could weigh on long‑term upside if competitors advance. Maze tumbles despite positive data for kidney disease drug

Insiders Place Their Bets

In other news, EVP Amit Sachdev sold 1,846 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $897,802.10. Following the completion of the transaction, the executive vice president owned 55,570 shares in the company, valued at approximately $27,026,469.50. This represents a 3.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the sale, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. This trade represents a 21.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 93,485 shares of company stock valued at $43,967,586. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.